Key Highlights
- NMRA shares are trading down 14.62% at $0.37, versus a prior close of about $0.43.
- Loss of $0.18 per share was narrower than the $0.27 market estimate.
- Cash and equivalents were $85.7 million, not enough for twelve months.
- Third-quarter net loss fell to $34.4 million from $56.8 million.
Neumora Therapeutics (NASDAQ:NMRA) shares are trading sharply lower today after its third-quarter filing said cash on hand does not cover operating plans for at least twelve months. The filing states that substantial doubt exists about the company's ability to continue as a going concern, even though the loss of $0.18 per share was narrower than the $0.27 market estimate.
The clinical-stage biopharmaceutical company develops brain-penetrant therapies. It is advancing NMRA-511 for agitation associated with Alzheimer's dementia and NMRA-898, a muscarinic compound.
Lower Spending Narrows the Loss
Third-quarter net loss was $34.4 million versus $56.8 million a year earlier, and the nine-month net loss was $131.0 million versus $177.5 million. Research and Development expense decreased $16.3 million, mainly from $13.1 million lower navacaprant costs after the Phase 3 program concluded in the second quarter. General and administrative expense fell 11% to $10.8 million on reduced headcount.
Navacaprant Setback and Funding Needs
In June 2026, the company announced that the Phase 3 KOASTAL-2 and KOASTAL-3 studies of navacaprant in major depressive disorder did not achieve statistical significance. It discontinued development in that indication and announced a reduction in force of about 35%. It had 60 full-time employees at September 30.
Cash and equivalents were $85.7 million at September 30. The company expects to obtain additional funding, but its plans are not fully implemented, so the filing concludes substantial doubt exists. Nine-month cash used in operations was $119.4 million.
Outlook: Financing and Pipeline Priorities Are the Next Tests
Investors will watch any Capital raise, progress on NMRA-511 and NMRA-898, and further cost actions.






Please wait processing your request...